Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

Related Keywords

Joshuak Sabari , ,Evolving Treatment Paradigm ,Advanced Non ,Small Cell Lung Cancer ,Second Line ,Non Small Cell Lung Cancer ,Nsclc ,Advanced Non Small Cell Lung Cancer ,Advanced Nsclc ,Nsclc Treatment ,Egfr Mutant Lung Cancer ,Egfr Mutated Lung Cancer ,Second Line Treatment ,Mariposa 2 ,